| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Boston Biomedical Research Institute,*
Watertown; and the Department of Neurology and Graduate Program inNeuroscience,
Harvard Medical School,Boston, Massachusetts
We found that up-regulation of major histocompatibility complex (MHC) class I expression accompanies, but is not required for, appearance of spontaneous myopathy in SJL/J mice. In some neuromuscular diseases, MHC class I expression is markedly up-regulated in muscles, though the consequences of this up-regulation for pathology are not clear. To study MHC class I in myopathy, we compared muscles of SJL/J mice to muscles of SJL/J mice that were also MHC class I-deficient due to targeted mutation in the ß-2-microglobulin gene (SJL/J B2m (-/-) mice). SJL/J mice show spontaneous myopathy and have a mutation in the dysferlin gene, a gene which is also mutated in human limb-girdle muscular dystrophy type 2B (LGMD2B). Muscles of eight-month-old SJL/J mice had higher levels of MHC class I expression than muscles of either C57BL/6J (wild-type) or SJL/J B2m (-/-) mice. In contrast, the percentage of abnormal muscle fibers was similar in SJL/J and SJL/J B2m (-/-) muscles. Invading Mac-1+ cells were most abundant in SJL/J B2m (-/-) muscles, moderately abundant in SJL/J muscles, and rare in C57BL/6J muscles. Thus, MHC class I was markedly up-regulated in SJL/J muscles, but this high level of MHC class I was not necessary for the appearance of myopathy.
This article has been cited by other articles:
 |
|
 |
|
  K. Wenzel, J. Zabojszcza, M. Carl, S. Taubert, A. Lass, C. L. Harris, M. Ho, H. Schulz, O. Hummel, N. Hubner, et al. Increased Susceptibility to Complement Attack due to Down-Regulation of Decay-Accelerating Factor/CD55 in Dysferlin-Deficient Muscular Dystrophy J. Immunol., November 1, 2005; 175(9): 6219 - 6225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Dominov, A. J. Kravetz, M. Ardelt, C. A. Kostek, M. L. Beermann, and J. B. Miller Muscle-specific BCL2 expression ameliorates muscle disease in laminin {alpha}2-deficient, but not in dystrophin-deficient, mice Hum. Mol. Genet., April 15, 2005; 14(8): 1029 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Cenacchi, M Fanin, L B De Giorgi, and C Angelini Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism J. Clin. Pathol., February 1, 2005; 58(2): 190 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mercuri, M. Poppe, R. Quinlivan, S. Messina, M. Kinali, L. Demay, J. Bourke, P. Richard, C. Sewry, M. Pike, et al. Extreme Variability of Phenotype in Patients With an Identical Missense Mutation in the Lamin A/C Gene: From Congenital Onset With Severe Phenotype to Milder Classic Emery-Dreifuss Variant Arch Neurol, May 1, 2004; 61(5): 690 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Lennon, A. Kho, B. J. Bacskai, S. L. Perlmutter, B. T. Hyman, and R. H. Brown Jr. Dysferlin Interacts with Annexins A1 and A2 and Mediates Sarcolemmal Wound-healing J. Biol. Chem., December 12, 2003; 278(50): 50466 - 50473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Campanaro, C. Romualdi, M. Fanin, B. Celegato, B. Pacchioni, S. Trevisan, P. Laveder, C. De Pitta, E. Pegoraro, Y. K. Hayashi, et al. Gene expression profiling in dysferlinopathies using a dedicated muscle microarray Hum. Mol. Genet., December 15, 2002; 11(26): 3283 - 3298. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
